Growth-hormone release
Sermorelin directly stimulates the pituitary through the GHRH receptor.
Explore the research →GROWTH-HORMONE RELEASING HORMONE
Sermorelin
A GHRH fragment that encourages the pituitary to release growth hormone, creating interest around growth, recovery and body composition.
Growth hormoneIGF-1Pituitary function
Human endocrine evidence with historical clinical useSermorelin can stimulate pituitary GH release. Historical paediatric studies showed increased growth velocity in selected children, but modern wellness claims extend beyond that evidence.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Sermorelin?
Sermorelin works by encouraging the pituitary to release the body's own growth hormone. That connection naturally creates interest around growth, recovery, body composition and sleep, although the strongest human evidence comes from endocrine testing and paediatric growth research.
Growth in GH deficiency
Historical studies reported improved growth velocity in some children with idiopathic GH deficiency.
Explore the research →Recovery & body composition
GH biology explains interest in recovery and lean mass.
Explore the research →Sleep & wellbeing
Night-time GH physiology has encouraged interest around sleep and wellbeing.
Explore the research →THE SCIENCE BIT
A short GHRH message for the pituitary.
Sermorelin is the active 1–29 fragment of GHRH. It stimulates the pituitary's GHRH receptor and encourages growth-hormone release, followed by downstream IGF-1 signalling.
This relies on the person's own endocrine response. Historical diagnostic and paediatric evidence is more specific than general adult claims about sleep, recovery or anti-ageing.
See the studies & trials →- GHRH receptor
- Pituitary stimulation
- GH
- The hormone released
- IGF-1
- A downstream response
How this connects to the research
Human endocrine evidence with a narrower historical clinical context.
FROM MOLECULE TO TISSUE
Where Sermorelin connects with the body
These are the tissues and biological systems behind the interest in Sermorelin.
- Pituitary
- Hormone secretion.
- Liver
- IGF-1 production.
- Growth-responsive tissues
- Downstream endocrine effects.
The research behind the interest
Growth-hormone release
Sermorelin directly stimulates the pituitary through the GHRH receptor.
Human endocrine testing clearly demonstrates GH release.
Established human mechanismExplore the studies →Growth in GH deficiency
Historical studies reported improved growth velocity in some children with idiopathic GH deficiency.
This is a defined paediatric endocrine context, not evidence for adult anti-ageing use.
Historical clinical evidenceExplore the studies →Recovery & body composition
GH biology explains interest in recovery and lean mass.
Direct evidence that sermorelin improves these outcomes in otherwise healthy adults is limited.
Limited direct evidenceExplore the studies →Sleep & wellbeing
Night-time GH physiology has encouraged interest around sleep and wellbeing.
Clinical benefit for sleep itself has not been established by robust sermorelin trials.
Mechanistic rationaleExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableSermorelin in diagnosis and treatment of idiopathic growth-hormone deficiency ↗
Children with suspected or diagnosed GH deficiency
Sermorelin stimulated GH release and increased growth velocity in some treated children.
Transient flushing and injection-site discomfort were among commonly reported adverse effects.
Subcutaneous GHRH for short stature ↗
11 children without classic GH deficiency
SubcutaneousSix months
Growth velocity increased during treatment in the study cohort.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
Human diagnostic and historical treatment studies are available.
✓
Clinical efficacyDeveloping
3/5 evidence depth
Growth efficacy was demonstrated in selected paediatric populations; broader wellness efficacy is unproven.
◇
Safety evidenceDeveloping
3/5 evidence depth
Short-term tolerability is described, but modern long-term off-label use is less well characterised.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
GHRH/GH physiology is well established.
HOW TO READ THESE SCORESDeveloping preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Sermorelin research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Growth hormone
RESEARCH AREA 02IGF-1
RESEARCH AREA 03Pituitary function
RESEARCH AREA 04Growth
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Sermorelin
Modern interest centres on GH release, recovery, sleep and body composition.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Sleep that feels more restorative
Adult interest often centres on waking less tired and feeling more recovered. The GHRH mechanism explains the appeal but does not establish a reliable sleep benefit in this setting.
- What makes a report informative
- Sleep continuity and daytime readiness.
- What can muddy the picture
- Sleep routines, stress and other compounds can change the same outcomes.
Training recovery and capability
People hope to recover between sessions and retain physical capacity. Historical endocrine evidence is more specific than these broader adult wellness goals.
- What makes a report informative
- Comparable training performance and recovery.
- What can muddy the picture
- A GH or IGF-1 response does not by itself prove better functional recovery.
Body composition and age-related wellbeing
Interest includes a leaner appearance and feeling less affected by ageing. These goals need actual clinical or functional outcomes rather than a hormone result described as rejuvenation.
- What makes a report informative
- Strength, waist and specific daily capabilities.
- What can muddy the picture
- Paediatric or diagnostic evidence cannot establish general adult anti-ageing benefit.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Growth-hormone release
Human endocrine testing clearly demonstrates GH release.
Evidence context: Established human mechanism
Growth in GH deficiency
This is a defined paediatric endocrine context, not evidence for adult anti-ageing use.
Evidence context: Historical clinical evidence
Recovery & body composition
Direct evidence that sermorelin improves these outcomes in otherwise healthy adults is limited.
Evidence context: Limited direct evidence
Sleep & wellbeing
Clinical benefit for sleep itself has not been established by robust sermorelin trials.
Evidence context: Mechanistic rationale
The biological rationale
Sermorelin is the active 1–29 fragment of GHRH. It stimulates the pituitary's GHRH receptor and encourages growth-hormone release, followed by downstream IGF-1 signalling.
This relies on the person's own endocrine response. Historical diagnostic and paediatric evidence is more specific than general adult claims about sleep, recovery or anti-ageing.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Historical endocrine protocols exist, but they should not be treated as a validated adult wellness or anti-ageing schedule.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial example
Community example · not clinically validatedHistorical paediatric growth-hormone studies used indication-specific, weight-based protocols. They do not establish this fixed adult community example.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–2 | 200 mcg |
| Weeks 3–4 | 300 mcg |
| Weeks 5–6 | 400 mcg |
| Weeks 7–8 | 500 mcg |
Frequency: Every day · 1 entry per scheduled day.
This is a finite editorial example. Its ending does not establish a safe course, break or repeat cycle. No repeat is added automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Pituitary stimulation is an endocrine intervention
What the current evidence saysSermorelin affects the GH/IGF axis. The clinical significance of repeated use depends on age, endocrine status, indication and monitoring.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Original publicationSermorelin in diagnosis and treatment of idiopathic growth-hormone deficiencyJournal / DOI ↗Bibliographic recordSermorelin in diagnosis and treatment of idiopathic growth-hormone deficiencyPubMed ↗Bibliographic recordSubcutaneous GHRH for short staturePubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesDrugs@FDA ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
Sermorelin is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.